Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Research & Development (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Research & Development over the past 12 years, most recently at $10.0 million for Q4 2025.

  • Quarterly results put Research & Development at $10.0 million for Q4 2025, down 86.1% from a year ago — trailing twelve months through Dec 2025 was $259.7 million (up 9.01% YoY), and the annual figure for FY2025 was $338.9 million, up 42.26%.
  • Research & Development for Q4 2025 was $10.0 million at Viridian Therapeutics, Inc.\DE, down from $86.3 million in the prior quarter.
  • Over the last five years, Research & Development for VRDN hit a ceiling of $86.6 million in Q2 2025 and a floor of $5.6 million in Q4 2022.
  • Median Research & Development over the past 5 years was $34.5 million (2023), compared with a mean of $39.1 million.
  • Biggest five-year swings in Research & Development: skyrocketed 588.52% in 2023 and later crashed 86.1% in 2025.
  • Viridian Therapeutics, Inc.\DE's Research & Development stood at $22.4 million in 2021, then crashed by 74.99% to $5.6 million in 2022, then skyrocketed by 588.52% to $38.6 million in 2023, then soared by 86.63% to $72.0 million in 2024, then crashed by 86.1% to $10.0 million in 2025.
  • The last three reported values for Research & Development were $10.0 million (Q4 2025), $86.3 million (Q3 2025), and $86.6 million (Q2 2025) per Business Quant data.